KR20200043970A - 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법 - Google Patents

고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법 Download PDF

Info

Publication number
KR20200043970A
KR20200043970A KR1020207000227A KR20207000227A KR20200043970A KR 20200043970 A KR20200043970 A KR 20200043970A KR 1020207000227 A KR1020207000227 A KR 1020207000227A KR 20207000227 A KR20207000227 A KR 20207000227A KR 20200043970 A KR20200043970 A KR 20200043970A
Authority
KR
South Korea
Prior art keywords
ipr
high affinity
selective binding
lys
binding ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207000227A
Other languages
English (en)
Korean (ko)
Inventor
쥔거 장
량 정 옌
Original Assignee
메인라인 바이오사이언스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메인라인 바이오사이언스 filed Critical 메인라인 바이오사이언스
Priority to KR1020237034343A priority Critical patent/KR20230145543A/ko
Publication of KR20200043970A publication Critical patent/KR20200043970A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207000227A 2017-09-05 2018-02-17 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법 Ceased KR20200043970A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237034343A KR20230145543A (ko) 2017-09-05 2018-02-17 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762554354P 2017-09-05 2017-09-05
US62/554,354 2017-09-05
PCT/US2018/018530 WO2019050564A1 (en) 2017-09-05 2018-02-17 CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USING THE SAME

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237034343A Division KR20230145543A (ko) 2017-09-05 2018-02-17 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법

Publications (1)

Publication Number Publication Date
KR20200043970A true KR20200043970A (ko) 2020-04-28

Family

ID=65635072

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207000227A Ceased KR20200043970A (ko) 2017-09-05 2018-02-17 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법
KR1020237034343A Ceased KR20230145543A (ko) 2017-09-05 2018-02-17 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237034343A Ceased KR20230145543A (ko) 2017-09-05 2018-02-17 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법

Country Status (6)

Country Link
EP (1) EP3679053A4 (enrdf_load_stackoverflow)
JP (1) JP2020532496A (enrdf_load_stackoverflow)
KR (2) KR20200043970A (enrdf_load_stackoverflow)
CN (1) CN111183146A (enrdf_load_stackoverflow)
CA (1) CA3065086A1 (enrdf_load_stackoverflow)
WO (1) WO2019050564A1 (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11123437B2 (en) 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
JP7541532B2 (ja) 2019-04-18 2024-08-28 プロビンシャル・ヘルス・サービシーズ・オーソリティ 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物
JP2023516878A (ja) * 2020-01-26 2023-04-21 メインライン バイオサイエンシーズ（シャンハイ）シーオー．，エルティーディ． 同位体標識された選択的ｃｘｃｒ４結合性ペプチドコンジュゲート並びにその作製方法及び使用方法
AU2023218802A1 (en) * 2022-02-11 2023-11-09 C-Biomex Co., Ltd. Peptide ligand targeting carbonic anhydrase ix, peptide construct comprising same, and uses thereof
CN114832113B (zh) * 2022-03-22 2023-06-20 重庆医科大学 疏水药物-马来酰亚胺衍生物及其主动载药脂质体和应用
WO2023201435A1 (en) * 2022-04-20 2023-10-26 Provincial Health Services Authority Cxcr4-targeting compounds, and methods of making and using the same
CN116023438B (zh) * 2023-02-06 2025-07-11 中国药科大学 一种cxcr4靶向多肽及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1991562A2 (en) * 2006-02-27 2008-11-19 Technische Universität München Cancer imaging and treatment
PT2160221E (pt) * 2007-05-30 2011-09-12 Lilly Co Eli Péptidos cíclicos antagonistas de cxcr4
IT1397901B1 (it) * 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
CN102626522B (zh) * 2012-04-12 2014-09-10 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
AU2012381808B2 (en) * 2012-06-06 2017-04-27 Polyphor Ag Beta-hairpin peptidomimetics
US9790286B2 (en) * 2013-01-02 2017-10-17 Lucia Irene Gonzalez Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis
AU2014396468B2 (en) * 2014-06-06 2019-02-21 Technische Universitat Munchen Modified cyclopentapeptides and uses thereof

Also Published As

Publication number Publication date
EP3679053A1 (en) 2020-07-15
CA3065086A1 (en) 2019-03-14
WO2019050564A1 (en) 2019-03-14
CN111183146A (zh) 2020-05-19
JP2020532496A (ja) 2020-11-12
EP3679053A4 (en) 2021-10-27
KR20230145543A (ko) 2023-10-17

Similar Documents

Publication Publication Date Title
KR20200043970A (ko) 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법
KR101169846B1 (ko) 시클릭 펩티드 ｃｘｃｒ４ 길항제
KR100668546B1 (ko) 수용체에 결합하는 펩티드 및 화합물
US9073974B2 (en) RGD-containing cyclic peptides
US10870681B2 (en) CXCR4 antagonists and methods of use
US11883501B2 (en) Selective CXCR4 binding peptide conjugate and methods for making and using the same
US10639379B2 (en) High affinity CXCR4 selective binding conjugate and method for using the same
WO2001083693A2 (en) Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses
EP1539803B1 (en) Fluoro-alkyl-cyclopeptide derivatives having anti-integrin activity
EP4097120A1 (en) Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same
US20240082346A1 (en) Composition Comprising an Antiviral Agent and a CXCR4 Selective Antagonist and Methods For Using the Same
HK1141474B (en) Cyclic peptide cxcr4 antagonists

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination